About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality.

Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology.

Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Overview of Role: The Director, Global Collaborations Business Operations & Strategy, is a pivotal leader role that sits at the center of Summit’s external partnerships execution, driving the operational, project, and strategic work required to bring combination studies to life with partner pharmaceutical companies. This individual is the primary operational lead for partner-sponsored combinations studies, but also a strategic contributor to externalized operational strategy, clinical study design strategy, and complementing Search & Evaluation diligence. This leader will work in partnership with the Alliance Management Lead, together forming a core team that owns each external collaboration end-to-end.

While the Alliance Management Lead stewards the partner relationship and joint governance, this Director delivers operational depth, cross-functional coordination, and strategy-to-execution translation across each combinations study program. Position reports to the VP, Business Development & Strategy Alliances, and will be a key member of a comprehensive team working across the arc of external focused growth, strategy to execution. Internally, the Director will mobilize and align a broad global, cross-functional team — Clinical, Research, Biomarker, Program Management, Medical Writing, Regulatory Affairs, CMC/Supply, Quality, Legal, Finance, and others — engaging leaders, SMEs, and executives to ensure every function is focused and synchronized to deliver on partnered programs.

The Director role brings visibility, broad scope of work and real ownership: the ideal candidate thrives in a high-agency environment, leads through influence, and brings both the operational rigor and strategic acumen to help Summit build an exceptional external growth engine.

Responsibilities

: Collaborations Operations Leadership & Partner Studies Oversight Own operational leadership for externally sponsored combination studies.